| ¿µ¹® | fetal monitoring | ÇÑ±Û | žư¨½Ã |
|---|---|---|---|
| ¼³¸í | ÀӽŠÁßÀ̳ª ºÐ¸¸ ÁßÀÇ Å¾ÆÀÇ »óŸ¦ ¾Ë¾Æº¸´Â °ÍÀ» žư¨½Ã¶ó°í ÇÑ´Ù. ¿©±â¿¡´Â ¿©·¯ °¡Áö ¹æ¹ýÀÌ Àִµ¥ Å©°Ô ºÐ¸¸Àü žư¨½Ã¿Í ºÐ¸¸Áß Å¾ư¨½Ã·Î Å©°Ô ³ª´«´Ù. 1. ºÐ¸¸Àü žư¨½Ã´Â ºÐ¸¸Çϱâ ÀÌÀüÀÇ Å¾ÆÀÇ »óŸ¦ °Ë»çÇÏ´Â ¹æ¹ýÀ¸·Î ´ÙÀ½°ú °°Àº ¿©·¯ °¡Áö ¹æ¹ýÀÌ ÀÖ´Ù. 1)¾ç¼öõÀÚ-ÁÖ»ç±â¸¦ ÀÌ¿ëÇØ¼ »ê¸ðÀÇ ¹è¸¦ ÅëÇØ¼ ¾ç¼ö¸¦ ¾ò¾î¼ ºÐ¼®ÇÏ¿© žÆÀÇ »óŸ¦ ¾Ë¾Æº¸´Â ¹æ¹ý. ÀӽŠ15ÁÖ À̻󿡼 ½Ç½ÃÇÒ ¼ö°¡ ÀÖ´Ù. 2)ÅÈÁÙõÀÚ-ÃÊÀ½ÆÄ°Ë»ç¸¦ ½Ç½ÃÇÏ¿© ¿µ»óÀ» º¸¸é¼ ÅÈÁÙ¼Ó¿¡ ¹Ù´ÃÀ» ³Ö¾î¼ ±×°÷ÀÇ Ç÷°üÀ» ã¾Æ Ç÷¾×À» äÃëÇÏ¿© °Ë»çÇÏ´Â ¹æ¹ý. 3)½ºÆ®·¹½º°Ë»ç-žƵµ Àڱüӿ¡¼ ¿îµ¿À» ÇÑ´Ù. ±×¸®°í Á¤»óÀûÀ¸·Î žư¡ Àڱüӿ¡¼ ¿îµ¿À» ÇÒ °æ¿ì¿¡´Â žÆÀÇ ½ÉÀå ¹Úµ¿ÀÌ »¡¶óÁö°Ô µÈ´Ù. žÆÀÇ ¿îµ¿°ú žÆÀÇ ½ÉÀå¹Úµ¿À» µ¿½Ã¿¡ °¨½ÃÇÏ¿© ¿îµ¿½Ã¿¡ žÆÀÇ ½ÉÀå¹Úµ¿ÀÌ »¡¶óÁö´Â °¡¸¦ ¾Ë¾Æº¸´Â °ÍÀÌ´Ù. 4)žÆÃ»°¢Àڱذ˻ç-30ÁÖ ÀÌ»óÀÌ µÈ žƴ ¼Ò¸®ÀÇ Àڱؿ¡ ´ëÇØ¼ ¹ÝÀÀÀ» ÇÑ´Ù. Áï ¼Ò¸®¸¦ µé·ÁÁÖ¾úÀ» °æ¿ì¿¡ žư¡ ¹ÝÀÀÀ» ÇØ¼ ½ÉÀåÀÇ ¹Úµ¿¼ö°¡ Áõ°¡¸¦ ÇÑ´Ù. 5)¼öÃེƮ·¹½º°Ë»ç-Á¤»óÀûÀΠžƴ ÀÚ±ÃÀÌ ¼öÃàÇϸé ÀÌ¿¡ ¹ÝÀÀÀ» ÇØ¼ ½É¹Ú¼ö°¡ º¯ÈÇÑ´Ù. À̰ÍÀ» ÀÌ¿ëÇÏ¿© žÆÀÇ »óŸ¦ °Ë»çÇÏ´Â ¹æ¹ýÀÌ´Ù. 2. ºÐ¸¸Áß Å¾ư¨½Ã ºÐ¸¸µµÁß¿¡ žÆÀÇ °Ç°»óŸ¦ °¨½ÃÇÏ´Â °ÍÀÌ´Ù. ´ëü·Î ºÐ¸¸µµÁß¿¡ žư¡ Àú»ê¼ÒÁõÀ̳ª ¿©·¯ °¡Áö Ãæ°ÝÀ» ¹Þ´Â °æ¿ì°¡ ¸¹À¸¹Ç·Î ºÐ¸¸µµÁßÀÇ Å¾ư¨½Ã´Â Áß¿äÇÑ Àǹ̸¦ °¡Áø´Ù. 1)ÀüÀڽĞư¨½Ã-Àü±âÀû ÀåÄ¡¸¦ ÀÌ¿ëÇÏ¿© žÆÀÇ »óŸ¦ ¾Ë¾Æº¸´Â °ÍÀ¸·Î °¨½ÃÀÇ ´ë»óÀº ÀÚ±ÃÀÇ ¼öÃà°ú žÆÀÇ ½ÉÀå¹Úµ¿¼öÀÌ´Ù. 2)žƸӸ®µ¤°³ Ç¥º»Ã¤Ãë Ç÷¾×-ºÐ¸¸µµÁß¿¡ žÆÀÇ µÎÇÇÀÇ Ç÷°ü¿¡¼ Ç÷¾×À» äÃëÇÏ¿© °Ë»ç¸¦ ÅëÇØ¼ žÆÀÇ »óŸ¦ ¾Æ´Â ¹æ¹ýÀÌ´Ù. ÁÖ·Î °Ë»ç¸¦ ÇàÇÏ´Â Á¾¸ñÀº Ç÷¾×ÀÇ pHÀÌ´Ù. |
||
| ¿µ¹® | fetal assessment | ÇÑ±Û | žƻçÁ¤ |
|---|---|---|---|
| ¼³¸í | ÀӽŠÁßÀ̳ª ºÐ¸¸ ÁßÀÇ Å¾ÆÀÇ »óŸ¦ ¾Ë¾Æº¸´Â °ÍÀ» žư¨½Ã¶ó°í ÇÑ´Ù. ¿©±â¿¡´Â ¿©·¯ °¡Áö ¹æ¹ýÀÌ Àִµ¥ Å©°Ô ºÐ¸¸Àü žư¨½Ã¿Í ºÐ¸¸Áß Å¾ư¨½Ã·Î Å©°Ô ³ª´«´Ù. 1. ºÐ¸¸Àüžư¨½Ã: ºÐ¸¸Çϱâ ÀÌÀüÀÇ Å¾ÆÀÇ »óŸ¦ °Ë»çÇÏ´Â ¹æ¹ýÀ¸·Î ´ÙÀ½°ú °°Àº ¿©·¯ °¡Áö ¹æ¹ýÀÌ ÀÖ´Ù. ¨ç ¾ç¼öõÀÚ: ÁÖ»ç±â¸¦ ÀÌ¿ëÇØ¼ »ê¸ðÀÇ ¹è¸¦ ÅëÇØ¼ ¾ç¼ö¸¦ ¾ò¾î¼ ºÐ¼®ÇÏ¿© žÆÀÇ »óŸ¦ ¾Ë¾Æº¸´Â ¹æ¹ý. ÀӽŠ15ÁÖ À̻󿡼 ½Ç½ÃÇÒ ¼ö ÀÖ´Ù. ¨è ÅÈÁÙõÀÚ: ÃÊÀ½ÆÄ°Ë»ç¸¦ ½Ç½ÃÇÏ¿© ¿µ»óÀ» º¸¸é¼ ÅÈÁÙ ¼Ó¿¡ ¹Ù´ÃÀ» ³Ö¾î¼ ±× °÷ÀÇ Ç÷°üÀ» ã¾Æ Ç÷¾×À» äÃëÇÏ¿© °Ë»çÇÏ´Â ¹æ¹ý. ¾ÆÁÖ À§ÇèÇÒ °Í °°Áö¸¸ »ó´çÈ÷ ¾ÈÀüÇÑ °ÍÀ¸·Î µÇ¾î ÀÖ´Ù. ´Ù¸¥ °Ë»ç¿¡ ºñÇØ¼ °Ë»ç¿¡ ¸¹Àº ±â¼úÀÌ ÇÊ¿äÇÏÁö¸¸ ¾ÆÁÖ ¸¹Àº Á¤º¸¸¦ Á¦°øÇØ ÁØ´Ù. ¨é ºñ½ºÆ®·¹½º°Ë»ç(nonstress test) : žƵµ Àڱà ¼Ó¿¡¼ ¿îµ¿À» ÇÑ´Ù. ±×¸®°í Á¤»óÀûÀ¸·Î žư¡ Àڱà ¼Ó¿¡¼ ¿îµ¿À» ÇÒ °æ¿ì¿¡´Â žÆÀÇ ½ÉÀå ¹Úµ¿ÀÌ »¡¶óÁö°Ô µÈ´Ù. žÆÀÇ ¿îµ¿°ú žÆÀÇ ½ÉÀå¹Úµ¿À» µ¿½Ã¿¡ °¨½ÃÇÏ¿© ¿îµ¿½Ã¿¡ žÆÀÇ ½ÉÀå¹Úµ¿ÀÌ »¡¶óÁö´Â °¡¸¦ ¾Ë¾Æº¸´Â °ÍÀÌ´Ù. |
||
| ¿µ¹® | fetal alcohol syndrome | ÇÑ±Û | žƾËÄÚ¿ÃÁõÈıº |
|---|---|---|---|
| ¼³¸í | ÀӽűⰣ Áß ¸¸¼ºÀûÀ¸·Î ¾ËÄÚ¿ÃÀ» ¼·ÃëÇÑ ¿©ÀÚ¿¡°Ô¼ ÅÂ¾î³ ¿µ¾Æ¿¡°Ô ³ªÅ¸³ª´Â ÇüŹ߻ýÀÇ ÀÌ»óÀ» ³ªÅ¸³»´Â ÁõÈıºÀ¸·Î¼ À§ÅλÀ¹ßÀ°ºÎÀü, ¾Õ¸Ó¸®¿Í ¾Æ·¡ÅÎÀÇ µ¹Ãâ, ªÀº°Ë¿, ÀÛÀº¾È±¸Áõ, ´«±¸¼®ÁÖ¸§, ½ÉÇÑ ¼ºÀåÁö¿¬, Á¤½ÅÁöü µîÀ» ³ªÅ¸³½´Ù. |
||
| HCG, hCG | Human Chorionic Gonadotropin; »ç¶÷À¶¸ð¼º¼º¼±ÀÚ±ØÈ£¸£¸ó 1. Placental Glycoprotein Hormone &nbs... |
|---|---|
| FN | false negative; fibronectin; fluoride number |
| FNL | fibronectin-like |
| FNR | fibronectin receptor |
| FNRA | fibronectin receptor alpha |
| fFN | Fetal fibronectin |
|---|---|
| cFN | Cellular fibronectin |
| FN | Fibronectin |
| FnBP | Fibronectin binding proteins |
| FN-R | fibronectin receptor |
| fetal | Of or pertaining to a foetus, pertaining to in utero development after the embryonic period. (18 Nov 1997) |
|---|---|
| receptors, fibronectin | Specific sites or molecular structures on or in cells with which fibronectins react or to which they bind. Studies have shown that these receptors function in certain types of adhesive contact as well as playing a major role in matrix assembly. These are the traditional fibronectin receptors, also called vla-5 receptors or alpha 5 beta 1 integrins. There are also other integrins that bind fibronectin, including alpha v beta 1. (12 Dec 1998) |
| plasma fibronectin | A circulating a2-glycoprotein that functions as an opsonin, mediating reticuloendothelial and macrophage clearance of fibrin microaggregates, collagen debris, and bacterial particulates, protecting microvascular perfusion and lymphatic drainage. (05 Mar 2000) |
| fibronectin | <protein> Glycoprotein of high molecular weight (2 chains each of 250 kD linked by disulphide bonds) that occurs in insoluble fibrillar form in extracellular matrix of animal tissues and soluble in plasma, the latter previously known as cold insoluble globulin. The various slightly different forms of fibronectin appear to be generated by tissue specific differential splicing of fibronectin mRNA, transcribed from a single gene. Fibronectins have multiple domains that confer the ability to interact with many extracellular substances such as collagen, fibrin and heparin and also with specific membrane receptors on responsive cells. Notable is the RGD domain recognised by integrins and two repeats of the EGF like domain. Interaction of a cells fibronectin receptors (members of the integrin family) with fibronectin adsorbed to a surface results in adhesion and spreading of the cell. (18 Nov 1997) |
| fibronectin hexapeptide N-acetylgalactosaminyltransferase | <enzyme> Enzyme from foetal and malignant tissues recognizing the sequence val-thr-his-pro-gly-tyr in fibronectin Registry number: EC 2.4.1.- Synonym: udp-galnac-vthpgy alpha-galnac transferase, hexapeptide-galnac-transferase (26 Jun 1999) |
| fibronectin laminase | <enzyme> Fibronectin fragment which has been activated by calcium chloride to produce a calcium-dependent proteolytic activity that splits preferentially laminin and denatured collagen type 1; cleaves the ala-gly bond in the sequence gpagpr; the arginine residue in position p3' is important for this cleavage Registry number: EC 3.4.99.- Synonym: fn-laminase (26 Jun 1999) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|